Search results
Showing 7486 to 7500 of 8232 results
Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife (IPG85)
Interventional procedures, IPG85 - Issued: August 2004 --> This guidance has been updated and replaced by NICE interventional procedures guidance 715.
Percutaneous intradiscal radiofrequency thermocoagulation for lower back pain (IPG83)
Interventional procedures, IPG83 - Issued: August 2004 --> This guidance has been updated and replaced by NICE interventional procedure guidance 545.
Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)
This evidence summary has been withdrawn. An NHS England clinical commissioning policy statement on biologic therapies for the treatment of juvenile idiopathic arthritis is available.
Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)
This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.
Critical limb ischaemia in peripheral vascular disease: intravenous iloprost (ESUOM24)
April 2019: This evidence summary has been withdrawn because a product containing intravenous iloprost with a marketing authorisation for treating critical limb ischaemia in peripheral vascular disease is now available in the UK.
November 2024: This evidence summary has been withdrawn because licensed products are now available.
Axonics sacral neuromodulation system for overactive bladder and faecal incontinence (MIB164)
This advice has been updated and replaced by NICE medical technologies guidance 50.
October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.
Process manual for the endorsement of guidance and quality standard support resources (PMG29)
The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.
February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.
Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)
February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.
This medtech innovation briefing has been updated and replaced by NICE's early value assessment guidance on Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.
myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)
This advice has been updated and replaced by NICE medical technologies guidance 68.
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)
This guidance has been updated and replaced by NICE technology appraisal guidance 527.
This guideline has been updated and replaced by NICE guideline NG101.